Skip to Content

Join the 'Gengraf' group to help and get support from people like you.

Gengraf News

New Kidney Transplant Drug Cuts Risk of Earlier Death: Study

Posted 28 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 27, 2016 – A newer drug used for preventing organ rejection might improve the long-term outlook for kidney transplant recipients, a new study finds. Over seven years, patients given the drug belatacept (brand name: Nulojix) were 43 percent less likely to die or see their donor kidney fail compared to patients given an older drug called cyclosporine. Experts said the findings should encourage more doctors and patients to choose belatacept over standard anti-rejection medications. "This is a potentially transformational drug," said study lead researcher Dr. Flavio Vincenti, a transplant specialist at the University of California, San Francisco. The study – funded by the drug's maker, Bristol-Myers Squibb – was published in the Jan. 28 issue of the New England Journal of Medicine. Belatacept was first approved by the U.S. Food and Drug Administration in 2011 for ... Read more

Related support groups: Renal Failure, Kidney Infections, Restasis, Cyclosporine, Chronic Kidney Disease, Organ Transplant - Rejection Prophylaxis, Peritoneal dialysis, Organ Transplant, Neoral, Organ Transplant - Rejection Reversal, Pyelonephritis, Renal Osteodystrophy, Gengraf, Graft-versus-host disease, Rejection Prophylaxis, Sandimmune, Nulojix, Hyperphosphatemia of Renal Failure, Belatacept

More New Drugs a Bad Fit With Grapefruit, Study Finds

Posted 26 Nov 2012 by Drugs.com

MONDAY, Nov. 26 – Because of new chemical formulations, prescription drugs that interact badly with grapefruit have more than doubled in number since 2008, yet many doctors seem unaware of this, Canadian researchers report. "The number of drugs on the market with the potential to produce serious adverse and in many cases life-threatening effects when combined with grapefruit has markedly increased over the past few years from 17 to 43 in four years," said lead researcher David Bailey, from the Lawson Health Research Institute in London, Ontario. "There is much greater need for health care professionals to understand grapefruit/drug interactions and to apply this information to the safer use of these drugs in their clinical practice," Bailey said. Even small amounts of grapefruit or grapefruit juice have the potential to cause sudden death, acute kidney failure, respiratory failure, ... Read more

Related support groups: Plavix, Lipitor, Simvastatin, Atorvastatin, Pravastatin, Amiodarone, Clopidogrel, Nifedipine, Zocor, Cyclosporine, Adalat, Pravachol, Procardia, Procardia XL, Cordarone, Neoral, Nifedical XL, Nifediac CC, Adalat CC, Pacerone

Newer Psoriasis Drugs May Lower Heart Attack Risk for Patients

Posted 20 Aug 2012 by Drugs.com

MONDAY, Aug. 20 – People with psoriasis who take a new class of drugs known as tumor necrosis factor (TNF) inhibitors may be at a lower risk for heart attack than their counterparts who only use topical medications to treat this inflammatory skin condition, a new study shows. And patients taking older systemic medicines and phototherapy may also have a reduced heart attack risk compared to those using topical preparations, the study found. Of 8,845 study participants, about 57 percent were treated with topical therapy only, 19 percent received a TNF inhibitor for at least two months and about 24 percent were treated with other medications or phototherapy. People who were treated with TNF inhibitors had a 50 percent lower risk, and those treated with other psoriasis drugs or phototherapy had a 46 percent lower risk for heart attack, than those who used topical medications alone. The ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Psoriasis, Humira, Enbrel, Remicade, Cyclosporine, Cimzia, Simponi, Soriatane, Infliximab, Neoral, Adalimumab, Etanercept, Acitretin, Golimumab, Gengraf, Sandimmune, Certolizumab, Trexall

Organ-Rejection Drug Linked to Higher Cancer Risk After Liver Transplant

Posted 28 Jun 2010 by Drugs.com

MONDAY, June 28 – Cyclosporine, a drug commonly used to prevent organ rejection following a transplant, has been linked to a significantly increased risk of developing cancer after liver transplant, new Dutch research reveals. The study was done in part to examine what role drugs that suppress the immune system might play in the development of cancer in liver transplant patients, whose long-term survival rates have improved little over the past three decades. Cancer is one of the leading causes of late death, and appears to be directly related to the intensity and cumulative doses of immunosuppressive drugs, according to researchers. The Dutch study compared cyclosporine and tacrolimus – the cornerstone of immunosuppressive drug therapy – in the occurrence of de novo (new) malignancies after transplantation. To do so, researchers analyzed the records of 385 liver transplant patients ... Read more

Related support groups: Cyclosporine, Neoral, Gengraf, Sandimmune

FDA Medwatch Alert: Immunosuppressant Drugs: Required Labeling Changes

Posted 14 Jul 2009 by Drugs.com

Sirolimus (marketed as Rapamune), Cyclosporine (marketed as Sandimmune and generics), Cyclosporine modified (marketed as Neoral and generics), Mycophenolate mofetil (marketed as Cellcept and generics), Mycophenolic acid (marketed as Myfortic)   The FDA is requiring the makers of certain immunosuppressant drugs to update their labeling to reflect that immunosuppressed patients are at increased risk for opportunistic infections, such as activation of latent viral infections, including BK virus-associated nephropathy. These immunosuppressant drugs are used to protect against the rejection of certain organ transplants. The association of BK virus-associated nephropathy has previously been reported for another immunosuppressant drug, tacrolimus (marketed as Prograf). Monitoring for this serious risk and early intervention by the health care provider is critical. Adjustments in ... Read more

Related support groups: CellCept, Myfortic, Rapamune, Gengraf

Licorice May Block Absorption of Organ Transplant Drug

Posted 24 Mar 2009 by Drugs.com

TUESDAY, March 24 – People taking the immunosuppressant cyclosporine should avoid consuming licorice because it may weaken the drug's effectiveness and possibly lead to deadly consequences, new research suggests. Chemists in Taiwan report that lab rats taking cyclosporine – commonly used to help prevent organ rejection in transplant patients – who were feed licorice or its main active ingredient, glycyrrhizin, did not absorb the medication well. For a transplant patient on cyclosporine, lowered levels of the medication could lead to rejection of the new organ, followed by illness and even death, said the researchers, who were to present their findings Tuesday at the American Chemical Society's annual meeting in Salt Lake City. "I would suggest that transplant patients avoid taking licorice," researcher Pei-Dawn Lee Chao, a chemist at China Medical University in Taichung, Taiwan, said ... Read more

Related support groups: Gengraf

More Juices Found to Affect Drugs' Effectiveness: Study

Posted 19 Aug 2008 by Drugs.com

TUESDAY, Aug. 19 – Grapefruit juice, long known to boost the absorption of certain medications, isn't the only juice that doesn't mix well with drugs, according to the Canadian researcher who first identified the ill effects of grapefruit juice. Other common juices, including orange and apple, may limit the body's absorption of drugs, compromising their effectiveness, said David Bailey, a professor of medicine and pharmacology at the University of Western Ontario, in London, Ontario, Canada. Bailey was expected to present his research Tuesday at the American Chemical Society's national meeting, in Philadelphia. "The original finding is that [grapefruit juice] markedly boosts the amount of drug that gets into the bloodstream," Bailey said. He first reported that nearly 20 years ago when he discovered that grapefruit juice increased the body's blood levels of the drug felodipine ... Read more

Related support groups: Cipro, Levaquin, Allegra, Tenormin, Plendil, Sporanox, Tenoretic, Gengraf, Etopophos

Ask a Question

Further Information

Related Condition Support Groups

Crohn's Disease, Inflammatory Bowel Disease, Psoriasis, Organ Transplant - Rejection Prophylaxis, Ulcerative Colitis, Rheumatoid Arthritis, Idiopathic (Immune) Thrombocytopenic Purpura, Organ Transplant - Rejection Reversal

Gengraf Patient Information at Drugs.com